Business, Drugs and Pharmaceuticals, Free News Articles, Product Launches

Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines

PFLUGERVILLE, Texas -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Nasal administration provides needle free, rapid systemic uptake into the body via the nose. Nasal delivery of vaccines can invoke a fast local immune response in the respiratory track, which is frequently the primary route of infection for contagious pathogens such as pandemic flu or coronavirus. The ZEOx1 OrionMRQ™ device is intuitive to use, enabling either patient self-administration or administration by caregivers with configurations available for both adults and children.

The OrionMRQ reloadable nasal delivery device has the capability to store up to four unit doses in the on-board storage compartment. The device is compact making it easy to carry in a pocket or purse. Zeteo intranasal delivery devices incorporate novel packaging technology utilizing a Form Fill Seal (FFS) flexible foil, packaging the drug or vaccine in a unit dose blister reducing the cost and eliminating the supply chain constraints of glass vials.

ZEOx1™ blister packaging provides exceptional barrier properties to protect the drug or vaccine during storage and transport and can be stored at room temperature, refrigerated or frozen storage conditions. The ZEOx1™ packaging technology is commercially scalable to produce millions of doses per day; a critically important requirement for rapid, cost effective deployment of vaccines and medical countermeasures to global populations.

About Zeteo Biomedical LLC:

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology, drug/device combination product development services and fill/finish packaging technology for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Related link: https://www.zeteobiomed.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2(TM) Delivery Platform, along with technical services to support the evaluation of a room temperature stable SARS-CoV-2 vaccine under development by ISU's Nanovaccine Institute.

Zeteo ZEO(TM) Delivery Platforms provide nasal delivery device configurations to support vaccine development during early stage pre-clinical animal studies, human clinical trials and are commercially scalable to fill/finish and deliver millions of doses per day for a global supply of nasal vaccines or medical countermeasures in the event of a pandemic crisis.

ISU's vaccine is expected to provide long-term protection against SARS-CoV-2, the novel coronavirus that causes COVID-19, and is intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single dose nasal self-administration as key capabilities.

"Our approach leverages the strengths of ISU's nanovaccine platform and Zeteo's ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up," said Dr. Balaji Narasimhan, Director of the Nanovaccine Institute at Iowa State University.

Zeteo's ZEOx2 Delivery Platform includes nasal delivery devices to support powder and reconstituted powder to liquid vaccine formulations that can be either caregiver- or self-administered.

Timothy Sullivan, President of Zeteo Biomedical, said "We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19."

Additional collaboration partners involved in the project include the Southwest Research Institute (San Antonio, TX), Skroot Laboratory, Inc. (Ames, IA), and the University of Iowa (Iowa City, IA). This is a fast track project and is expected to be completed by the end of the year.

About Zeteo Biomedical LLC

Zeteo Biomedical(TM) is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Related link: https://www.zeteobiomed.com/

This news story was published by the Neotrope® News Network - all rights reserved.